Atnaujinkite slapukų nuostatas

Colorectal Cancer [Kietas viršelis]

Edited by , Edited by , Edited by
  • Formatas: Hardback, 368 pages, aukštis x plotis: 229x152 mm, weight: 612 g
  • Išleidimo metai: 11-Sep-2006
  • Leidėjas: CRC Press Inc
  • ISBN-10: 0824728351
  • ISBN-13: 9780824728359
Kitos knygos pagal šią temą:
Colorectal CancerDidesnis paveikslėlis
  • Formatas: Hardback, 368 pages, aukštis x plotis: 229x152 mm, weight: 612 g
  • Išleidimo metai: 11-Sep-2006
  • Leidėjas: CRC Press Inc
  • ISBN-10: 0824728351
  • ISBN-13: 9780824728359
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780824728359.html
Raktažodžiai:
Written by world authorities on the subject, this reference comprehensively covers every aspect of colorectal cancer. Addressing the molecular mechanisms, genetics, identification, and therapy of disease, this guide covers new pharmaceutical developments, current screening protocols, and modern methods of disease management by specialists at renowned institutions such as the Royal Marsden Hospital, the Memorial Sloan Kettering Cancer Center, and the Vanderbilt-Ingram Cancer Center.
Preface v
Contributors xiii
1. Genetic Susceptibility to Colorectal Cancer
1(42)
Rebecca A. Barnetson and Malcolm G. Dunlop
Introduction
1(1)
Autosomal Dominant Disorders
2(13)
Familial Adenomatous Polyposis
15(5)
Other Defined Dominant Colorectal Cancer Susceptibility Syndromes
20(1)
Autosomal Recessive Disorders
21(3)
Low Penetrance Variants
24(6)
Conclusions
30(1)
References
31(12)
2. Epidemiology of Colorectal Cancer
43(34)
Julian Little and Linda Sharp
Introduction
43(1)
Descriptive Epidemiology of Colorectal Cancer
43(3)
Groups at Increased Risk of Colorectal Cancer
46(1)
Risk Factors for Colorectal Neoplasia
47(12)
Conclusion
59(1)
References
60(17)
3. Colorectal Cancer Screening
77(26)
Robert J.C. Steele
Introduction
77(1)
Principles of Screening
78(2)
Colorectal Cancer as a Suitable Target for Screening
80(2)
Fecal Occult Blood Screening
82(3)
Flexible Sigmoidoscopy
85(1)
Colonoscopy
86(2)
Radiology
88(1)
Comparative Studies
88(1)
Harm Caused by Screening
89(2)
Economics of Screening
91(2)
Novel Approaches to Screening
93(4)
Conclusions
97(1)
References
97(6)
4. Pathology
103(22)
Christian Wittekind
Introduction
103(1)
Definition
103(1)
Site Distribution
104(1)
Gross Morphology
104(1)
Histomorphology
105(2)
Special Clinical Types of Colorectal Cancer
107(3)
Classification of Anatomical Extent Before Treatment
110(3)
Classification of Anatomical Extent After Treatment
113(1)
Histological Grading of Tumor Regression
114(1)
Prognostic Factors
114(1)
The Histopathological Report
114(2)
Quality Management Within Pathology Departments
116(1)
Pathology Findings in Resection Specimens Indicative of Oncological Quality of Surgery
116(3)
Quality Assurance of Clinical Trials on Adjuvant and Neoadjuvant Therapy: The Surgical Pathologist's Point of View
119(1)
Malignant Tumors Other than Carcinomas
120(1)
References
121(4)
5. Familial Cancer Management
125(26)
Sabine Tejpar
Introduction
125(2)
Main Hereditary Colorectal Cancer Syndromes
127(12)
Peutz—Jeghers Syndrome
139(2)
Juvenile Polyposis
141(2)
Cowden Syndrome or PTEN Hamartoma Syndrome
143(1)
Familial Gastric Cancer
144(1)
Familial Pancreatic Cancer
144(1)
Hereditary Mixed Polyposis
144(1)
Familial Colorectal Cancer
145(1)
Aspects of Genetic Testing for GI Cancer Susceptibility
146(2)
References
148(3)
6. The Surgical Principles of Managing Colorectal Cancer
151(12)
Ian R. Daniels and Richard J. Heald
Introduction
151(1)
The "Embryological Approach" to Rectal Cancer
152(1)
The Multidisciplinary Approach
152(1)
The Principles of Rectal Cancer Excision: Total Mesorectal Excision
152(4)
Recurrence and Survival
156(2)
Applying the Principles of Total Mesorectal Excision to Colonic Cancer
158(1)
Conclusion
159(1)
References
159(4)
7. Adjuvant Therapy for Colorectal Cancer
163(32)
Geoff Chong and David Cunningham
Introduction
163(1)
Adjuvant Therapy for Stage III Colorectal Cancer
164(9)
Adjuvant Therapy for Stage II Colorectal Cancer
173(3)
Newer Agents for Adjuvant Therapy
176(7)
Prognostic Factors and Adjuvant Therapy
183(2)
Recommendations for Adjuvant Therapy
185(1)
Conclusions
186(1)
References
187(8)
8. The Role of Radiotherapy in the Treatment of Rectal Cancer
195(34)
Rob Glynne-Jones and Rob Hughes
Background
195(2)
Indications for Adjuvant Radiotherapy
197(1)
Risk Factors for Local Recurrence
198(3)
The Evidence Base for Adjuvant Radiotherapy in Resectable Rectal Cancer
201(2)
The Rationale for Short Course Preoperative Radiotherapy
203(1)
Short Course Preoperative Radiotherapy vs. Surgery Alone or Postoperative Radiotherapy
204(1)
More Recent Trials Performed with Chemoradiation
205(3)
Fixed/Unresectable Rectal Cancer
208(1)
Intraoperative Radiotherapy
209(1)
Early Rectal Cancer
209(2)
Pretreatment Clinical Assessment
211(1)
Radiotherapy Planning Techniques
212(2)
Acute Toxicity and Supportive Care During Radiotherapy
214(1)
Timing of Surgery Following Preoperative Radiotherapy
215(1)
Surgical Complications
216(1)
Late Effects
216(1)
Conclusion
217(2)
References
219(10)
9. The Treatment of Metastatic Colorectal Cancer
229(24)
Eric Van Cutsem and Leonard Saltz
Introduction
229(1)
Cytotoxic Agents in Metastatic CRC
230(6)
Targeted Therapies for Metastatic CRC
236(8)
References
244(9)
10. Hepatic Directed Therapy 253(34)
Gregory D. Leonard and Nancy E. Kemeny
Introduction
253(1)
Hepatic Arterial Infusion Chemotherapy
254(17)
Portal Vein Infusion Chemotherapy
271(1)
Isolated Hepatic Perfusion Chemotherapy
272(2)
Conclusion
274(1)
References
275(12)
11. Pharmacogenomics of Colorectal Cancer 287(30)
Patrick Johnston, Wendy L. Allen, and Howard L. McLeod
Introduction
287(1)
Loss of Heterozygosity
288(1)
Microsatellite Instability
289(1)
TGF β II Mutation
290(1)
5-Fluorouracil
291(5)
Oxaliplatin
296(2)
Irinotecan
298(1)
Novel Therapies
299(2)
Vascular Endothelial Growth Factor
301(1)
New Technologies
302(4)
Conclusions
306(1)
References
306(11)
12. Drug Development for Advanced Colorectal Cancer in the United States 317(20)
Igor Puzanov and Mace L. Rothenberg
Introduction
317(1)
Development of 5-FU and 5-FU/LV as First-Line Chemotherapy
318(1)
Development of Capecitabine as an Oral Alternative to 5-FU
319(1)
Development of Irinotecan as Second-Line Therapy
320(1)
Integration of Irinotecan into Front-Line Chemotherapy
321(1)
Oxaliplatin: Initial Data on Front-Line Therapy
322(1)
Oxaliplatin: Demonstration of Second-Line Efficacy
323(1)
N9741: Comparison of First-Line Combination Regimens
324(1)
Bevacizumab
325(2)
Cetuximab
327(1)
Regulatory Considerations of the U.S. FDA in the Approval of New Drugs for Treatment of Advanced Colorectal Cancer
328(1)
Endpoints for New Drug Approval for Colorectal Cancer in the United States
329(2)
How Will New Drugs be Developed for Colorectal Cancer in the Future?
331(2)
References
333(4)
Index 337


Jim Cassidy

Patrick Johnston

Eric van Cutsem